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Botulinum Toxin A for the Treatment of Dyshidrotic Hand Eczema
Abstract
Background: Dyshidrotic hand eczema is a relatively common vesicobullous disorder of the palms and soles.
It is also known as pompholyx, dyshidrotic hand dermatitis, and palmoplantar eczema. It is characterized by
pruritic lesions that can erupt in a chronic or relapsing pattern with episodes lasting months to years.The
condition can be difficult to treat because of the thickness of the affected skin and the numerous sweat glands.
Current treatments are not always effective and pose their own risks. Studies have shown associations between
hyperhidrosis and dyshidrotic hand eczema. Botulinum toxin A (BTXA) has been used to treat hyperhidrosis
with success. This leads to the possibility that BTXA may be an effective treatment option for refractory cases
of dyshidrotic hand eczema.
Methods: An exhaustive search of available medical literature was conducted using Medline-OVID, EBMR
Multifile, CINAHL, and Web of Science. The keywords dyshidrotic eczema, eczema, pompholyx, and
botulinum toxins were used in the search. The relevant articles were evaluated for quality using Grading of
Recommendations, Assessment, Development and Evaluation (GRADE) criteria.
Results: Two prospective control studies met inclusion criteria and were included in this systematic review.
The first study investigated whether BTXA injections used with topical corticosteroids could treat dyshidrotic
hand eczema better than topical therapy alone. Eight adult patients were enrolled with dyshidrotic hand
eczema. Itching and vesiculation were inhibited earlier when using both BTXA and corticosteroids compared
to corticosteroids alone. The second study evaluated the effects of BTXA injections as a treatment for
dyshidrotic hand eczema with the other hand as an untreated control. Ten patients with bilateral hand eczema
enrolled in the study. There were significant reductions in patient important outcomes and disease processes
in the BTXA treatment hand compared to the control.
Conclusion: BTXA can be a reasonable treatment option for patients with refractory dyshidrotic hand
eczema. This treatment may be even more valuable in patients with hyperhidrosis.
Degree Type
Capstone Project
Degree Name
Master of Science in Physician Assistant Studies
First Advisor
James Ferguson, PA-C
Second Advisor
Annjanette Sommers, PA-C, MS
Keywords
Botulinum toxin A, dyshidrotic hand eczema, pompholyx
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/466
Subject Categories
Medicine and Health Sciences
Rights
Terms of use for work posted in CommonKnowledge.
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/466
Copyright and terms of use
If you have downloaded this document directly from the web or from CommonKnowledge, see the
“Rights” section on the previous page for the terms of use.
If you have received this document through an interlibrary loan/document delivery service, the
following terms of use apply:
Copyright in this work is held by the author(s). You may download or print any portion of this document
for personal use only, or for any use that is allowed by fair use (Title 17, §107 U.S.C.). Except for personal
or fair use, you or your borrowing library may not reproduce, remix, republish, post, transmit, or
distribute this document, or any portion thereof, without the permission of the copyright owner. [Note:
If this document is licensed under a Creative Commons license (see “Rights” on the previous page)
which allows broader usage rights, your use is governed by the terms of that license.]
Inquiries regarding further use of these materials should be addressed to: CommonKnowledge Rights,
Pacific University Library, 2043 College Way, Forest Grove, OR 97116, (503) 352-7209. Email inquiries
may be directed to:. copyright@pacificu.edu
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/466
 
 
NOTICE TO READERS 
 
This work is not a peer-reviewed publication.  The Master’s Candidate author of this 
work has made every effort to provide accurate information and to rely on authoritative 
sources in the completion of this work.  However, neither the author nor the faculty 
advisor(s) warrants the completeness, accuracy or usefulness of the information provided 
in this work.  This work should not be considered authoritative or comprehensive in and 
of itself and the author and advisor(s) disclaim all responsibility for the results obtained 
from use of the information contained in this work.  Knowledge and practice change 
constantly, and readers are advised to confirm the information found in this work with 
other more current and/or comprehensive sources. 
 
The student author attests that this work is completely his/her original authorship and that 
no material in this work has been plagiarized, fabricated or incorrectly attributed.         
 
 Botulinum Toxin A for the Treatment of Dyshi
A Clinical Graduate Project Submitted to the Faculty of the
School of Physician Assistant Studies
For the Masters of Science Degree, 
Faculty Advisor: 
Clinical Graduate Project Coordinator: Annjanette Sommers, PA
 
- 1 - 
Hand Eczema  
 
 
 
 
 
 
 
 
Rebecca J Schultz 
 
 
 
 
 
 
 
 
 
 
Pacific University 
Hillsboro, OR 
August 9.2014 
 
James Ferguson, PA-C 
 
 
drotic 
 
-C, MS 
 - 2 -  
Biography 
Rebecca Schultz is a native of Washington where she majored in Kinesiology at 
Washington State University in 2010. She spent the next few years working as a CNA in 
Washington. She then moved to Wyoming with her husband and worked in the operating 
room. After completing PA school she plans to join her Husband in Alaska on the Kenai 
Peninsula. She enjoys hiking, fishing, and exploring both Alaska and Washington with 
her husband and dog. Her professional interests are family medicine, women’s health, 
and dermatology.  
  
 - 3 -  
Abstract   
Background:  Dyshidrotic hand eczema is a relatively common vesicobullous disorder of 
the palms and soles. It is also known as pompholyx, dyshidrotic hand dermatitis, and 
palmoplantar eczema. It is characterized by pruritic lesions that can erupt in a chronic or 
relapsing pattern with episodes lasting months to years. The condition can be difficult to 
treat because of the thickness of the affected skin and the numerous sweat glands. Current 
treatments are not always effective and pose their own risks. Studies have shown 
associations between hyperhidrosis and dyshidrotic hand eczema. Botulinum toxin A 
(BTXA) has been used to treat hyperhidrosis with success. This leads to the possibility 
that BTXA may be an effective treatment option for refractory cases of dyshidrotic hand 
eczema.  
 
Methods: An exhaustive search of available medical literature was conducted using 
Medline-OVID, EBMR Multifile, CINAHL, and Web of Science. The keywords 
dyshidrotic eczema, eczema, pompholyx, and botulinum toxins were used in the search. 
The relevant articles were evaluated for quality using Grading of Recommendations, 
Assessment, Development and Evaluation (GRADE) criteria. 
 
Results:  Two prospective control studies met inclusion criteria and were included in this 
systematic review. The first study investigated whether BTXA injections used with 
topical corticosteroids could treat dyshidrotic hand eczema better than topical therapy 
alone. Eight adult patients were enrolled with dyshidrotic hand eczema. Itching and 
vesiculation were inhibited earlier when using both BTXA and corticosteroids compared 
to corticosteroids alone. The second study evaluated the effects of BTXA injections as a 
treatment for dyshidrotic hand eczema with the other hand as an untreated control. Ten 
patients with bilateral hand eczema enrolled in the study. There were significant 
reductions in patient important outcomes and disease processes in the BTXA treatment 
hand compared to the control. 
 
Conclusion:  BTXA can be a reasonable treatment option for patients with refractory 
dyshidrotic hand eczema. This treatment may be even more valuable in patients with 
hyperhidrosis.  
 
Keywords:  Botulinum toxin A, dyshidrotic hand eczema, pompholyx 
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Botulinum Toxin A for the Treatment of 
Dyshidrotic Hand Eczema 
BACKGROUND 
 Dyshidrotic hand eczema is a vesicobullous disorder of the palms and soles.1 It is 
also known as pompholyx, dyshidrotic hand dermatitis, and palmoplantar eczema. It is 
characterized by pruritic lesions that can erupt in a chronic or relapsing pattern with 
episodes lasting months to years.2-4 The condition can be difficult to treat because of the 
thickness of the affected skin and the numerous sweat glands.1  
The current standard of care is topical corticosteroids. These often have to be used 
long term, which poses concerns. Other treatments that have been effective are 
calcineurin inhibitors, topical photochemotherapy, systemic photochemotherapy, or 
systemic corticosteroids. For refractory cases immunosuppressants have been used. All of 
these therapies pose risks of their own.1   
Dyshidrotic eczema can be difficult to treat, especially when triggers are difficult 
to avoid. The vesiculations are cosmetically concerning. More importantly they affect 
daily and occupational activities. The itching and burning is aggravating. It is not 
uncommon for excoriations to lead to secondary infections with staphylococci.1 It would 
be beneficial for a treatment to be longer lasting with fewer side effects. 
 The exact etiology of the disease has not been determined, however, there are a 
number of provoking factors. Sensitivity to nickel has been explored and appears to be an 
aggravating factor.5,6 Other factors include constant wetting of the hands, occlusion and 
sweating.2-4 Hyperhidrosis has been shown to be an aggravating factor in almost 40% of 
cases and the disease is more common in the summer months.5 Sweating is regulated by 
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sudoriferic nerve endings. Acetylcholine is the major transmitter that stimulates eccrine 
gland activity. Botulinum toxin A (BTXA) is a selective and potent inhibitor of 
sudoriferic nerve endings. BTXA is able to inhibit acetylcholine release.7,8   Due to this 
mechanism BTXA has been used in past years to treat hyperhidrosis with success. 9,10 
Botulinum toxin A has the potential for use as a treatment for refractory cases of 
dyshidrotic hand eczema.  
METHODS 
 An exhaustive search of available medical literature was conducted using 
Medline-OVID, EBMR Multifile, CINAHL, and Web of Science. The keywords 
dyshidrotic eczema, eczema, pompholyx, and botulinum toxins were used in the search. 
Articles that studied the treatment of dyshidrotic hand eczema using botulinum toxin A 
(BTXA) injections and were included for review. The reference list of each relevant 
article was reviewed for additional pertinent studies. The studies also only included 
English language studies and those with human subjects. These relevant articles were 
evaluated for quality using Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE) criteria.11 
RESULTS 
 After combining the terms “eczema”, “dyshidrotic”, or “pompholyx” with 
“botulinum toxins” nine articles were retrieved. After reviewing for primary data and 
human studies, two articles12,13 met the inclusion criteria. Both articles were controlled 
prospective studies. See Table 1.  
Wollina et al 
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 This prospective controlled study12 investigated whether BTXA injections used 
with topical corticosteroids could treat dyshidrotic hand eczema. Eight adult patients 
were enrolled with atopic type dyshidrotic hand eczema. The study included five males 
and three females ages 29-32 years old. In all patients both hands were affected.12  
The eczema was evaluated based on a semi-objective grading system the 
Dyshidrotic Eczema Area and Severity Index (DASI).14 The DASI is based on number of 
vesicles, erythema, scaling, and itching, as well as the extent of the affected area. The 
maximum score is 60 points. This evaluation was done before treatment and after 1 week, 
4 weeks, and 8 weeks.12  
 Patients were also administered topical steroids that were selected based on the 
patient’s clinical presentation of the hand eczema. Each patient remained on the same 
topical steroid for the duration of the study and applied equally to both hands. The hand 
with the more severe DASI score was treated with BTXA injections in addition the 
topical preparation of steroid. “One hundred units of BTXA (Botox, Pharm Allergan, 
Germany) diluted with 2 mL physiological sodium chloride solution were injected 
intracutaneously in aliquots of 0.1 mL using a 30-guage needle along the fingers and in 
the palms.”12 
 At 8 weeks, six patients completed the study. In the control hands, which only 
topical corticosteroids were applied, inconsistent and limited improvement was seen in 
five of six hands. One patient’s DASI score increased. Only two patients saw 
improvement where the DASI score was less than 10 points.12 See Table 2.  
 However, all six of the hands treated with topical steroids in addition to BTXA 
showed significant improvement. At 8 weeks, none of the six patients had a DASI score 
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above 10 points. The BTXA group also showed faster relief from itching than steroids 
alone.12 See Figure 1. 
Swartling et al 
 This prospective controlled study13 evaluated the effects of BTXA injections as a 
treatment for dyshidrotic hand eczema. Ten patients, five women and five men, ages 22-
61 years with bilateral hand eczema enrolled in the study. At the beginning of the trial 
seven patients were using topical steroids and one had used systemic steroids. All ten had 
history of vesicular hand dermatitis, however, two of the ten may have also had hand 
psoriasis. It was noted that six patients had experienced hyperhidrosis.13  
 Patients were assessed using a semi quantitative evaluation of several variables. 
Each hand was evaluated for disease activity score based on the occurrence of erythema, 
scaling, infiltration, excoriation, crusting, and vesicles. Each trait was graded on a scale 
of 0-3 (0=none, 1=mild, 2=moderate, 3=severe), giving each hand a maximum score of 
18. The extent of the dermatitis was also evaluated based on the total area affected.  The 
same two investigators did these assessments before and after treatment. They evaluated 
the first patients together. Patients also estimated the effect of the BTXA injections on a 
5-point scale (none, slight, moderate, good, or very good). They also used a visual linear 
analogue scale (VAS) to indicate the extent of their itching before and after the 
injections.13 
 Prior to injection with BTXA, regional anesthesia of the ulnar and median nerves 
was administered. Either the right or left hand was injected with 20 microliters of BTXA, 
provided by Allergan Pharmaceuticals, every 15 mm on the volar aspects of the palms 
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and fingers. See Figure 2. The average total injected BTXA was 162 units. The opposite 
hand was left untreated to act as a control for follow-up.13 
 Two patients were lost to follow-up, one due to personal reasons and one due to 
failure of protocol. One patient was still evaluated with VAS before and after injections.13  
 Patients were evaluated at follow up visit between 28-59 days after injection 
(average 39 days). At completion 7 of 10 patients self reported good or very good 
treatment effect. One patient reported slight and two had none. The VAS score for itching 
decreased by 39% on the hand injected with BTXA and increased by 52% on the 
untreated control hand. The disease activity score decreased by 54% on the treated side 
and by 29% on the untreated. The occurrence of vesicles decreased by 74% on the treated 
side and 27% on the untreated side. Erythema was decreased by 53% on the treated side 
and 30% on untreated side. The extent of disease was decreased by 58% on the treated 
side versus 27% on the untreated side. There was minimal or no change seen in scaling, 
crusting, and excoriations.13 See Table 3.  
DISCUSSION 
 The data presented above indicates that botulinum toxin A may be an alternative 
treatment option for patients with dyshidrotic hand eczema. Patients with refractory cases 
of this disorder may benefit most from this treatment. Furthermore, using BTXA may 
confer longer lasting benefit than other topical therapies such as corticosteroids. The 
Swartling et al study13 did report the side effect of minimal transient muscle weakness in 
the hand.13 No other side effects were reported in either study. The use of regional 
anesthesia would greatly reduce pain and discomfort to the patient making this treatment 
option more tolerable.  
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It was observed in the Swartling et al study13 that patients with noted 
hyperhidrosis benefitted most from the treatment with six out of the seven patients that 
reported good or very good results having hyperhidrosis. While the etiology of 
dyshidrotic hand eczema is not completely clear, there does appear to be a link between 
sweating and the disease process. This could be due to sweat aggravating the skin and 
inducing itch in the atopic patient.13 The Wollina et al study12 also demonstrated that by 
interrupting sweating the hand eczema was able to heal. BTXA has been shown to 
decrease sweating and has been used for focal hyperhidrosis with success.9,10,15 In recent 
studies16,17 it has been shown that substance P release is also inhibited by BTXA, which 
may explain the antipruritic activity. 
Although both studies12,13 demonstrated promising results, there were limitations 
to both studies. In Wollina et al12 there was no allocation concealment. The hand with a 
more severe DASI score was used at the treatment hand, which may increase the chance 
of bias. There was also no blinding or randomization. Allocation concealment would 
have been difficult to accomplish, as the effects of BTXA are noticeable, such as 
transient weakness and anhidrosis. Nevertheless, no attempt was made to blind either 
patient or administer which may lead to performance bias. Patients also started the study 
with a range of disease severity. They were subsequently treated with different topical 
corticosteroid preparations. This could lead to performance bias, although unlikely as one 
hand acted as control. The use of the DASI provided a relatively objective scoring system 
and decreases detection bias. The study went to completion of 8 weeks. The small sample 
size of six patients completing the study seriously limits the precision. There is also the 
possibility of publication bias as the study was funded by a grant from Allergan 
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Pharmaceuticals, which produces Botox and provided its product for this study. This 
study was assessed using GRADE and due to these limitations its quality was determined 
to be very low.11,12 
The Swartling et al study13 also demonstrated limitations.  There was no 
allocation concealment, randomization, or blinding but with the use of one hand as 
treatment control it is unlikely that the study design had significant implications on the 
treatment effect. All patients were injected with same amount of BTXA, decreasing 
likelihood of performance bias. However, at the start of the trial 7 of the 10 patients had 
been on topical steroids and one of those had also used systemic steroids. This could 
impact results. Outcomes were measured with a semi-objective disease activity and 
extent of dermatitis grading system. The use of use of a VAS for itching and self-
estimation of treatment is relatively objective and introduces some level of detection bias.  
The same two investigators assessed patients using their scoring system, but did so 
separately after the first few patients also introducing some level of bias. The article does 
not disclose how the hand was chosen to receive treatment and does not take into account 
the difference in disease severity. There are slight prognostic differences between hands, 
most notably in the VAS for itching. See Table 3. The small sample size of 10 patients is 
a serious limitation to the precision of the study. It is unlikely that there is publication 
bias as funding was through county councils in Sweden. Botox product was supplied for 
the study from Allergan Pharmaceuticals. Overall, the quality of evidence was 
determined to be very low using GRADE.11,13  
Despite each study’s limitations the use of patient important outcomes and having 
a control ameliorates some concerns over the low quality of evidence. Having a double-
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blind study with placebo versus BTXA would be ideal. Further studies may benefit from 
larger population size.  
CONCLUSION 
 Botulinum toxin A has demonstrated to have strong potential to be a treatment for 
refractory cases of dyshidrotic hand eczema. The effectiveness and longevity of the 
treatment is promising. With use of regional anesthesia the process would be less 
problematic. Cost may be a barrier to treatment and make its use as the standard of care 
unlikely when corticosteroids are relatively low priced. Research to further knowledge of 
BTXA for this type of eczema is needed before it will likely become common practice 
for refractory cases. However, in refractory cases it should be considered as a valuable 
treatment option.  
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Table 1. GRADE evidence profile: Botulinum toxin A for treatment of dyshydrotic hand 
eczema  
 
Quality Assessment 
Downgrade Criteria 
Quality  Importance 
 Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Wollina et al study12  
 
Prospective 
Controlled 
Serious 
limitations 
Serious 
indirectness 
Serious 
imprecision 
No serious 
inconsistencies  
Bias likely 
Very 
low  
Critical  
Reasoning  
No blinding, 
no allocation 
concealment, 
No 
randomization 
Use of 
different 
adjuvant 
therapies  
Small 
sample size, 
No CI given 
Patient is own 
control, worse 
hand was 
treated 
Funded by 
pharmaceutical 
company 
  
Swartling et al study13 
 
Prospective 
controlled 
Serious 
limitations 
No serious 
indirectness 
Serious 
imprecision 
Serious 
inconsistencies 
Bias unlikely  
Very 
low 
Critical 
Reasoning  
No blinding, 
no allocation 
concealment, 
no 
randomization 
 
Small 
sample size, 
no CI given 
No disclosure 
how treatment 
hand was 
chosen 
Little funding 
from industry 
  
 
 
 
Table 2.  Improvement of Dyshidrotic Eczema Area and Severity Index score in 
dyshidrotic hand eczema: pretreatment vs. 8 weeks of follow-up adapted from Wollina et 
al study.12 
Patient Topical corticosteroids Topical corticosteroid plus botulinum toxin A 
Week 0 8 0 8 
1 19 38 19 0 
2 30 18 30 2 
3 9 8 11 3 
4 22 16 42 10 
5 42 8 60 1 
6 44 14 55 2 
Mean 28 17 36 3 
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Table 3. Summary of findings adapted from Swartling et al study.13 
 
 
 
 
Pruritus Score (VAS) Vesicle Occurrence Total Activity Score Effect 
Treated Untreated Treated Untreated Treated Untreated  
Patient Before After Before After Before After Before After Before After Before After  
1 7.3 1.2 7.3 7 3 0 3 3 11 2 11 10 Good 
2 1.5 0 1.5 2.3 2 1 2 1 4 2 4 4 Good 
3 5 2.5 5 5 2 0 2 1 9 2 9 4 Good 
4 2 0.2 2 8 - - - - - - - - Very good 
5 2.1 9.1 2.4 5.3 0 0 0 0 2 5 2 4 None 
6 3.2 0 3.2 0.5 1 0 1 1 6 3 6 6 Good 
7 3.9 3.6 2.5 2 3 2 3 1 11 7 11 5 None 
8 0.8 2.2 3 4.8 1 0 1 0 6 3 6 3 Slight 
9 5 0 1 7.6 3 1 3 3 9 4 9 7 Good 
10 0.4 0.2 0.5 0.7 0 0 0 1 7 1 7 3 Very good 
Median 2.6 0.7 2.4 4.9 2 0 2 1 7 3 7 4 Good 
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Figure 1.  Improvement of Dyshidrotic Eczema Area and Severity Index score with 
topical corticosteroids alone (a) and adjuvant botulinum toxin A (b) adapted from 
Wollina et al study.12 
a.  
 
b.  
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Figure 2.  Adapted schematic view of injection sites of BTXA from Swartling et al 
study.13 
 
 
